文献速递前列腺增生与排尿功能障碍

Aquablation与经尿道前列腺电切术治疗良性前列腺增生的随机对照试验:一年结局

Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes.
PubMed 文献 · Urology · 2018-12-12

这项双盲多中心随机对照试验将181例BPH相关中重度下尿路症状患者分配至Aquablation或TURP,比较1年安全性和疗效。结果显示两组IPSS下降均达15.1分,Qmax改善分别为10.3 cc/s与10.6 cc/s(P=.8632),PSA均降低1分,再治疗率TURP 1.5%、Aquablation 2.6%(P=NS),6个月后无手术相关不良事件。

要点

  • Aquablation与TURP在1年时症状评分和尿流率改善相似。
  • 两组PSA均显著降低1分且组间相似(P=.9125)。
  • 6个月后无手术相关不良事件,晚期并发症率低。

核心结论

  • TURP与Aquablation术后1年结局相似,晚期手术相关并发症率低。

研究设计与样本

  • 双盲、多中心、前瞻性随机对照试验,纳入181例BPH相关中重度下尿路症状患者,随机接受TURP或Aquablation。

主要发现

  • 12个月IPSS下降在TURP或Aquablation后均为15.1分。
  • 平均最大尿流率改善Aquablation为10.3 cc/s,TURP为10.6 cc/s(P=.8632)。
  • 1年时两组PSA均显著降低1分(P<.01),组间相似(P=.9125)。
  • 1年内因BPH再手术率TURP为1.5%,Aquablation为2.6%(P=NS)。
  • 6个月后无手术相关不良事件。

关键数值与推荐

  • 主要安全终点为Clavien-Dindo持续1级或2级及以上并发症的发生。

临床怎么用

  • Aquablation可作为BPH相关中重度下尿路症状患者与TURP疗效和安全性相当的选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report 1-year safety and efficacy outcomes after either Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) METHODS: This double-blinded, multicenter prospective randomized controlled trial assigned 181 patients with BPH-related moderate-to-severe lower urinary tract symptoms to either electrocautery-based prostate resection (TURP) or Aquablation. Efficacy endpoints included reduction in International Prostate Symptom Score and improvement in uroflow parameters. The primary safety endpoint was the occurrence of Clavien-Dindo persistent grade 1 or grade 2 or higher complications. RESULTS: BPH symptom score improvements were similar across groups with 12-month reduction of 15.1 points after TURP or Aquablation. In both groups, mean maximum urinary flow rates increased markedly postoperatively, with mean improvements of 10.3 cc/s for Aquablation versus 10.6 cc/s for TURP (P = .8632). At 1 year, Prostate-specific antigen (PSA) was reduced significantly (P < .01) in both groups by 1 point; the reduction was similar across groups (P = .9125). Surgical retreatment for BPH rates for TURP were 1.5% and Aquablation 2.6% within 1 year from the study procedure (P = not significant (NS)). The rate of late complications was low, with no procedure-related adverse events after month 6. CONCLUSION: The 1-year outcomes after TURP and Aquablation were similar and the rate of late procedure-related complications was low. (ClinicalTrials.gov number, NCT02505919).

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Gilling PJ, Barber N, Bidair M, et al. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. Urology. 2018. PMID: 30552937. doi:10.1016/j.urology.2018.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。